Stem cell models for cardiovascular disease
| Dates: | 15 May 2015 |
|---|
| Times: | 14:00 - 15:00 |
|---|
| What is it: | Seminar |
|---|
| Organiser: | Faculty of Life Sciences |
|---|
| Who is it for: | University staff, Current University students |
|---|
| Speaker: | Chris Denning |
|---|
|
|
This seminar is part of the Manchester Tissue Regeneration & Stem Cell Network seminar series. Sponsored by Millipore.
Over the last 15 years, human pluripotent stem cells (hPSCs) have progressed from an academic curiosity into a technology that underpins commerce, disease understanding, drug development and clinical translation. Reflecting on our experience in disease modelling, Cas9/CRISPR gene editing and drug development for cardiovascular disease, we will consider the opportunities and challenges faced by integrating high content automated technologies with hPSC biology. This includes the use of high content screening of microarrays of 10,000 polymers to identify affordable synthetic chemistries that support fully defined culture of hPSCs and that stimulate functional maturation of hPSC-derived cardiomyocytes. We have also developed a bespoke robotic platform to allow complete automation of hPSC culture and differentiation to cardiomyocytes (and hepatocytes). These developments in throughout are now presenting a phenotyping bottleneck, whereby production of hPSC-cardiomyocytes far outstrips our ability to assess biological outcomes. With this in mind, we have integrated phenotyping with high content platforms that allow assessment of structure (e.g. confocal plate reader imaging) and function (mitochondrial activity, contractility and electrophysiology). Overcoming similar challenges for other lineages will be equally important for the hPSC field to develop further.
Speaker
Chris Denning
Organisation: University of Nottingham
Travel and Contact Information
Find event
Lecture Theatre
Michael Smith Building
Manchester
